conducted a study on the ER+/HER2-low human breast cancer mouse xenotransplantation model, and the results showed that adding ET to the combination of anti-HER3 and anti-HER2 drugs could further improve the efficacy of tumor regression (55). The gene discussed is ESR1; the disease is breast cancer.